Developer of yeast-based therapeutic human antibodies designed to improve the quality of the therapeutic lead.
Drug Discovery📍 Lebanon, NHFounded 2007
Current Valuation
$1.1B
as of 2015-Q1
UNICORN
Developer of yeast-based therapeutic human antibodies designed to improve the quality of the therapeutic lead.
Company Profile
Founded
2007
HQ
Lebanon, NH
Employees
139
Total Raised
$142.56M
Last Round
Later Stage VC — $100M (Jan 2015)
IPO Status
private
Fundraising Status
Later Stage VC · $100M · 11y 7mo ago
privateTotal raised $142.56M
Secondary Market
Implied price / share
$57
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Later Stage VC
$100M
Jan 2015
—
$1.1B
BiotechnologyCollaborationHealth Care
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2015-Q1. Refreshed quarterly.